Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Bioxyne Limited ( (AU:BXN) ).
Bioxyne Limited announced a change in the director’s interest, with Mr. Anthony Ho participating in a capital raise approved by shareholders. This move, involving the acquisition and gifting of securities, reflects strategic adjustments in the company’s financial operations, potentially impacting its market positioning and shareholder value.
The most recent analyst rating on (AU:BXN) stock is a Buy with a A$0.04 price target. To see the full list of analyst forecasts on Bioxyne Limited stock, see the AU:BXN Stock Forecast page.
More about Bioxyne Limited
Bioxyne Limited operates in the biotechnology sector, focusing on the development and distribution of health and wellness products. The company primarily offers probiotic and immune health products, targeting both domestic and international markets.
Average Trading Volume: 2,764,348
Technical Sentiment Signal: Buy
Current Market Cap: A$85.4M
See more insights into BXN stock on TipRanks’ Stock Analysis page.